Incorporating thyroid markers in Down syndrome screening protocols

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F27661989%3A_____%2F17%3AN0000006" target="_blank" >RIV/27661989:_____/17:N0000006 - isvavai.cz</a>

Výsledek na webu

<a href="https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.5047" target="_blank" >https://obgyn.onlinelibrary.wiley.com/doi/10.1002/pd.5047</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/pd.5047" target="_blank" >10.1002/pd.5047</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Incorporating thyroid markers in Down syndrome screening protocols

Popis výsledku v původním jazyce

ObjectiveThe article aimed to assess the benefit of incorporating maternal serum thyroid disease marker levels (thyroid-stimulating hormone and free thyroxine) into first trimester Down syndrome screening protocols. MethodsStatistical modelling was used to predict performance with and without the thyroid markers. Two protocols were considered: the combined test and the contingent cell-free DNA (cfDNA) test, where 15-40% women are selected for cfDNA because of increased risk based on combined test results. Published parameters were used for the combined test, cfDNA and the Down syndrome means for thyroid-stimulating hormone and free thyroxine; other parameters were derived from a series of 5230 women screened for both thyroid disease and Down syndrome. ResultsCombined test: For a fixed 85% detection rate, the predicted false positive rate was reduced from 5.3% to 3.6% with the addition of the thyroid markers. Contingent cfDNA test: For a fixed 95% detection rate, the proportion of women selected for cfDNA was reduced from 25.6% to 20.2%. ConclusionsWhen screening simultaneously for maternal thyroid disease and Down syndrome, thyroid marker levels should be used in the calculation of Down syndrome risk. The benefit is modest but can be achieved with no additional cost. (c) 2017 John Wiley & Sons, Ltd.

Název v anglickém jazyce

Incorporating thyroid markers in Down syndrome screening protocols

Popis výsledku anglicky

ObjectiveThe article aimed to assess the benefit of incorporating maternal serum thyroid disease marker levels (thyroid-stimulating hormone and free thyroxine) into first trimester Down syndrome screening protocols. MethodsStatistical modelling was used to predict performance with and without the thyroid markers. Two protocols were considered: the combined test and the contingent cell-free DNA (cfDNA) test, where 15-40% women are selected for cfDNA because of increased risk based on combined test results. Published parameters were used for the combined test, cfDNA and the Down syndrome means for thyroid-stimulating hormone and free thyroxine; other parameters were derived from a series of 5230 women screened for both thyroid disease and Down syndrome. ResultsCombined test: For a fixed 85% detection rate, the predicted false positive rate was reduced from 5.3% to 3.6% with the addition of the thyroid markers. Contingent cfDNA test: For a fixed 95% detection rate, the proportion of women selected for cfDNA was reduced from 25.6% to 20.2%. ConclusionsWhen screening simultaneously for maternal thyroid disease and Down syndrome, thyroid marker levels should be used in the calculation of Down syndrome risk. The benefit is modest but can be achieved with no additional cost. (c) 2017 John Wiley & Sons, Ltd.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30200 - Clinical medicine

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Prenatal Diagnosis

ISSN

0197-3851

e-ISSN

1097-0223

Svazek periodika

37

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

510-514

Kód UT WoS článku

000401561200013

EID výsledku v databázi Scopus

2-s2.0-85018935336